Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (2020 - 2025)

Cytek Biosciences filings provide 6 years of Shares Outstanding readings, the most recent being $127.2 million for Q2 2025.

  • On a quarterly basis, Shares Outstanding fell 3.29% to $127.2 million in Q2 2025 year-over-year; TTM through Jun 2025 was $127.2 million, a 3.29% decrease, with the full-year FY2023 number at $130.7 million, down 3.44% from a year prior.
  • Shares Outstanding hit $127.2 million in Q2 2025 for Cytek Biosciences, down from $129.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $136.3 million in Q2 2023 to a low of $31.8 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $133.7 million (2021), compared with a mean of $120.5 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 6307.03% in 2021 and later decreased 4.26% in 2024.
  • Cytek Biosciences' Shares Outstanding stood at $133.7 million in 2021, then grew by 1.21% to $135.4 million in 2022, then decreased by 3.44% to $130.7 million in 2023, then fell by 0.73% to $129.8 million in 2024, then dropped by 1.99% to $127.2 million in 2025.
  • The last three reported values for Shares Outstanding were $127.2 million (Q2 2025), $129.8 million (Q3 2024), and $131.5 million (Q2 2024) per Business Quant data.